Talis Biomedical Corporation
TLIS · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $412 | $3,652 | $0 | $10,938 |
| % Growth | -88.7% | – | -100% | – |
| Cost of Goods Sold | $41 | $8,391 | $2,621 | $1,374 |
| Gross Profit | $371 | -$4,739 | -$2,621 | $9,564 |
| % Margin | 90% | -129.8% | – | 87.4% |
| R&D Expenses | $40,694 | $70,831 | $157,591 | $89,019 |
| G&A Expenses | $0 | $0 | $0 | $13,103 |
| SG&A Expenses | $28,214 | $40,729 | $42,418 | $13,103 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,722 | -$1,160 | -$2,621 | -$1,374 |
| Operating Expenses | $67,186 | $110,400 | $197,388 | $100,748 |
| Operating Income | -$66,815 | -$112,706 | -$200,009 | -$91,184 |
| % Margin | -16,217.2% | -3,086.1% | – | -833.6% |
| Other Income/Exp. Net | $4,808 | -$306 | $7,973 | $54 |
| Pre-Tax Income | -$62,007 | -$113,012 | -$192,036 | -$91,130 |
| Tax Expense | $0 | $0 | -$1,578 | -$54 |
| Net Income | -$62,007 | -$113,012 | -$190,458 | -$91,076 |
| % Margin | -15,050.2% | -3,094.5% | – | -832.7% |
| EPS | -34.12 | -63.65 | -126.13 | -314.06 |
| % Growth | 46.4% | 49.5% | 59.8% | – |
| EPS Diluted | -34.12 | -63.65 | -126.13 | -314.06 |
| Weighted Avg Shares Out | 1,818 | 1,776 | 1,510 | 290 |
| Weighted Avg Shares Out Dil | 1,818 | 1,776 | 1,510 | 290 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $54 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $770 | $11,601 | $2,621 | $1,374 |
| EBITDA | -$66,045 | -$101,411 | -$189,415 | -$89,756 |
| % Margin | -16,030.3% | -2,776.9% | – | -820.6% |